Serum N-glycan NA3Fb identified as a prognostic biomarker of poor outcome in HBV-related hepatocellular carcinoma.

ABSTRACT:

Background

Glycosylation, as one of the most prevalent forms of post-translational modification, plays a pivotal role in tumor progression through structural alterations of serum N-glycans in hepatocellular carcinoma (HCC). In this study, we systematically investigated these N-glycan profiles as potential prognostic biomarkers for predicting patient survival outcomes.

Methods

This study enrolled a cohort of 150 hepatitis B virus (HBV)-related HCC patients (BCLC stages A-D) who received treatment and follow-up monitoring at Southwest Medical University Hospital from 2022 to 2023. Additionally, 105 chronic hepatitis B (CHB) patients, 50 healthy individuals matched for age and gender were recruited as controls. Serum N-glycan profiles were characterized using capillary gel elec

SUBMITTER: Kang P 

PROVIDER: S-EPMC12825219 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature